Back to Search
Start Over
Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome.
- Source :
-
Frontiers in pharmacology [Front Pharmacol] 2024 Feb 12; Vol. 15, pp. 1337436. Date of Electronic Publication: 2024 Feb 12 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- IC <subscript>50</subscript> = 11 nM (PI3Kδ); 244 nM (PI3Kα); 424 nM (PI3Kβ), 2,230 nM (PI3Kγ).<br />Competing Interests: Author SD was employed by Conju-Probe. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2024 De.)
Details
- Language :
- English
- ISSN :
- 1663-9812
- Volume :
- 15
- Database :
- MEDLINE
- Journal :
- Frontiers in pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38410131
- Full Text :
- https://doi.org/10.3389/fphar.2024.1337436